그림 16. 피인용 수에 따른 특허 수의 분포
| ○ | 비만치료제 기술에 속하는 특허 63455편 중 (2019-2024년 출판된 특허), 적어도 1회 이상 인용된 특허 수는 14874편(23.44%)임. |
| ○ | 비만치료제 기술에 속하는 특허 중 피인용수가 높은 특허 리스트를 표 18 에 나타내었음. |
표 18. 고 피인용 특허 목록
| 번호 | 특허제목(미국특허번호) | 출원인 | 패밀리 특허번호 | 피인용 수 |
|---|---|---|---|---|
| 1 | Absorbable adhesives and their formulation for use in medical applications (10500309) |
COOK BIOTECH INC(US, IN, West Lafayette) | CA 2701183 A1 20090409; WO 2009045824 A2 20090409; WO 2009045824 A3 20100701; US 2009092651 A1 20090409; US 10500309 B2 20191210; GB 2465532 A 20100526; GB 201005602 D0 20100519; GB 2465532 B 20130123; AU 2008309087 A1 20090409 | 623 |
| 2 | Tissue thickness compensator configured to redistribute compressive forces (10624861) |
Ethicon LLC(US, PR, Guaynabo) | US 2022313619 A1 20221006; US 2020315983 A1 20201008; US 11559496 B2 20230124; US 2021259986 A1 20210826; US 2017367991 A1 20171228; US 10624861 B2 20200421; US 2021259987 A1 20210826; US 11850310 B2 20231226; US 2014205637 A1 20140724; US 9629814 B2 20170425 | 508 |
| 3 | Diagnosis, removal, or mechanical damaging of tumor using plasmonic nanobubbles (10471159) |
MASIMO CORP(US, CA, Irvine) | US 10471159 B1 20191112 | 328 |
| 4 | Opioid overdose monitoring (10932729) |
MASIMO CORP(US, CA, Irvine) | WO 2019236759 A1 20191212; EP 3801207 A1 20210414; US 2021128078 A1 20210506; US 11564642 B2 20230131; KR 20210013641 A 20210204; KR 102241960 B1 20210421; CN 112512406 A 20210316; US 2019374173 A1 20191212; US 10932729 B2 20210302; US 2019374139 A1 20191212; US 10939878 B2 20210309; US 2019374713 A1 20191212; US 11627919 B2 20230418; JP 7174778 B2 20221117; JP 2021520958 A 20210826 | 230 |
| 5 | Medicament preparation and treatment devices, methods, and systems (10478544) |
NXSTAGE MEDICAL, INC.(US, MA, Lawrence) | US 11167069 B2 20211109; US 2020009308 A1 20200109; US 2022047790 A1 20220217; US 2017290970 A1 20171012; US 10478544 B2 20191119; WO 2016049542 A3 20160519; EP 3197518 A4 20180620; WO 2016049542 A2 20160331; EP 3197518 B1 20190724; EP 3197518 A2 20170802; EP 3626279 A1 20200325; EP 3560532 B1 20230419; EP 3560532 A1 20191030 | 215 |
| 6 | Opioid overdose monitoring (10939878) |
MASIMO CORP(US, CA, Irvine) | WO 2019236759 A1 20191212; EP 3801207 A1 20210414; US 2021128078 A1 20210506; US 11564642 B2 20230131; KR 20210013641 A 20210204; KR 102241960 B1 20210421; CN 112512406 A 20210316; US 2019374173 A1 20191212; US 10932729 B2 20210302; US 2019374139 A1 20191212; US 10939878 B2 20210309; US 2019374713 A1 20191212; US 11627919 B2 20230418; JP 7174778 B2 20221117; JP 2021520958 A 20210826 | 210 |
| 7 | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects (10512643) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2018092906 A1 20180405; US 10512643 B2 20191224 | 100 |
| 8 | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects (10463634) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 10463634 B2 20191105; US 2018256518 A1 20180913; US 2017252309 A1 20170907; US 9968568 B2 20180515 | 100 |
| 9 | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects (10548857) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 10548857 B2 20200204; US 2019008801 A1 20190110; US 2017304229 A1 20171026; US 10105327 B2 20181023 | 99 |
| 10 | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan (10596167) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2016361305 A1 20161215; US 2017360776 A1 20171221; US 10092561 B2 20181009; US 10596167 B2 20200324; US 2019015407 A1 20190117 | 96 |
| 11 | Bupropion and dextromethorphan for treating nicotine addiction (10688066) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2019290601 A1 20190926; US 10688066 B2 20200623 | 95 |
| 12 | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects (10786469) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2020093762 A1 20200326; US 10786469 B2 20200929 | 88 |
| 13 | Combination of dextromethorphan and bupropion for treating depression (10799497) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 10799497 B2 20201013; US 2020147075 A1 20200514 | 88 |
| 14 | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects (10786496) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2018360823 A1 20181220; US 10786496 B2 20200929; US 2017281617 A1 20171005; US 10105361 B2 20181023 | 88 |
| 15 | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects (10780066) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 10080727 B2 20180925; US 2017304230 A1 20171026; US 2019008800 A1 20190110; US 10780066 B2 20200922 | 88 |
| 16 | Bupropion as a modulator of drug activity (10780064) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2020261431 A1 20200820; US 2020246280 A1 20200806; US 10780064 B2 20200922 | 88 |
| 17 | Bupropion as a modulator of drug activity (10772850) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2020230078 A1 20200723; US 10772850 B2 20200915 | 88 |
| 18 | Bupropion and dextromethorphan for treating nicotine addiction (10813924) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 10813924 B2 20201027; US 2020206217 A1 20200702 | 83 |
| 19 | Bupropion as a modulator of drug activity (10806710) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2016324807 A1 20161110; US 2017354619 A1 20171214; US 10058518 B2 20180828; US 10806710 B2 20201020; US 2019192450 A1 20190627 | 80 |
| 20 | Opioid overdose monitoring (11627919) |
MASIMO CORP(US, CA, Irvine) | WO 2019236759 A1 20191212; EP 3801207 A1 20210414; US 2021128078 A1 20210506; US 11564642 B2 20230131; KR 20210013641 A 20210204; KR 102241960 B1 20210421; CN 112512406 A 20210316; US 2019374173 A1 20191212; US 10932729 B2 20210302; US 2019374139 A1 20191212; US 10939878 B2 20210309; US 2019374713 A1 20191212; US 11627919 B2 20230418; JP 7174778 B2 20221117; JP 2021520958 A 20210826 | 79 |
| 21 | Bupropion as a modulator of drug activity (10864209) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2020230131 A1 20200723; US 10864209 B2 20201215 | 78 |
| 22 | Bupropion as a modulator of drug activity (10894047) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 10894047 B2 20210119; US 2020230130 A1 20200723 | 77 |
| 23 | Bupropion as a modulator of drug activity (10894046) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 10894046 B2 20210119; US 2020215055 A1 20200709 | 77 |
| 24 | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects (10881624) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2017360773 A1 20171221; US 10092560 B2 20181009; US 2016346276 A1 20161201; US 9763932 B2 20170919; US 10881624 B2 20210105; US 2019083426 A1 20190321 | 75 |
| 25 | Bupropion as a modulator of drug activity (10874664) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2020230129 A1 20200723; US 10874664 B2 20201229 | 75 |
| 26 | Bupropion as a modulator of drug activity (10874663) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2020222389 A1 20200716; US 10874663 B2 20201229 | 75 |
| 27 | Bupropion as a modulator of drug activity (10874665) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 10874665 B2 20201229; US 2020215058 A1 20200709 | 75 |
| 28 | Bupropion as a modulator of drug activity (10881657) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2019216798 A1 20190718; US 2020222388 A9 20200716; US 10881657 B2 20210105 | 75 |
| 29 | Biosensor performance indicator for intraoral appliances (10639134) |
ALIGN TECHNOLOGY INC(US, CA, San Jose) | US 2018368961 A1 20181227; US 10639134 B2 20200505; WO 2019005808 A1 20190103; US 2023149143 A1 20230518; US 2020214817 A1 20200709; US 11576766 B2 20230214 | 73 |
| 30 | Pharmaceutical compositions comprising meloxicam (10471014) |
AXSOME THERAPEUTICS, INC.(US, NY, New York) | US 2018280306 A1 20181004; US 10471014 B2 20191112 | 72 |
| 31 | Pharmaceutical compositions comprising meloxicam (10471069) |
AXSOME THERAPEUTICS, INC.(US, NY, New York) | CA 3049229 C 20210727; CA 3049229 A1 20180712; SI 3565550 T1 20210430; BR 112019013901 A2 20200204; AU 2022200590 A1 20220317; EP 3565550 B1 20201028; KR 20230017366 A 20230203; KR 102627411 B1 20240118; EP 3565550 A4 20200122; EP 3565550 A1 20191113; CO 2019008364 A2 20190820; NZ 755129 A 20211029; KR 20190122659 A 20191030; WO 2018129220 A1 20180712; ES 2845566 T3 20210727; EP 3789016 A1 20210310; HR P20210034 T1 20210402; AU 2018205790 B2 20200709; AU 2018205790 A1 20190725; LT 3565550 T 20210325; RS 61346 B1 20210226; CA 3121746 A1 20180712; JP 2023144095 A 20231006; US 2019070192 A1 20190307; US 10265324 B2 20190423; JP 2021107413 A 20210729; PL 3565550 T3 20210719; PT 3565550 T 20210120; MX 2021014509 A 20220106; US 2018256593 A1 20180913; US 10471068 B2 20191112; US 10137131 B2 20181127; US 2018214380 A1 20180802; AU 2020244610 A1 20210121; AU 2020244610 B2 20211104; HU E052749 T2 20211228; CY 1123820 T1 20220527; KR 102493541 B1 20230130; KR 20210107157 A 20210831; KR 20240013848 A 20240130; JP 2020503360 A 20200130; DK 3565550 T3 20210118; JP 6870867 B2 20210512; CN 110621314 A 20191227; US 2019231792 A1 20190801; US 10471069 B2 20191112; MX 2019008127 A 20191202 | 72 |